Company intelligence / Profile preview
Sistema
- Ownership
- Private
- Development stage
- Other
Overview
Sistema-BioTech has developed a proprietary technology for producing recombinant therapeutic proteins using CHO cell systems that achieves significantly higher protein yields compared to imported technologies used in Russia. The company developed COVID-19 diagnostic test systems, with over 7 million tests performed by mid-November 2021. They created a highly effective producer cell line for Adalimumab, a monoclonal antibody listed in Russia's vital and essential medicines (VED) list.
- Therapeutic areas
- ImmunologyWomen's HealthNeurologyDermatologyInfectious DiseasesGastroenterologyOncology
- Modalities
- Recombinant proteinMonoclonal antibody
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Sistema.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sistema.